• Home
  •  / Synthetic Biologics

Synthetic Biologics

OverviewSuggest Edit

Synthetic Biologics is a late-stage clinical company developing therapeutics designed to preserve the microbiome. The Company is developing an oral enzyme for the prevention of C. difficile infections, and a series of monoclonal antibody therapies for the treatment of Pertussis and Acinetobacter infections. In addition, it is developing a drug candidate for the treatment of relapsing-remitting multiple sclerosis and cognitive dysfunction in multiple sclerosis.

TypePublic
Founded2001
HQRockville, MD, USMap
Websitesyntheticbiologics.com
View Jobs

Recent NewsAll News

Latest Updates

Employees (est.) (Feb 2020)11(-15%)
Revenue (FY, 2011)$0
Share Price (Feb 2021)$1.2 (+33%)
Cybersecurity ratingAMore

Key People/Management at Synthetic Biologics

Steven Shallcross

Steven Shallcross

Chief Executive Officer, Chief Financial Officer, Treasurer and Secretary, Director
Jeffrey J. Kraws

Jeffrey J. Kraws

Chairman
Michael Kaleko

Michael Kaleko

Senior Vice President, Research & Development
Jeffrey Wolf

Jeffrey Wolf

Director
John Monahan

John Monahan

Director
Show more

Synthetic Biologics Office Locations

Synthetic Biologics has an office in Rockville
Rockville, MD, US (HQ)
9605 Medical Center Dr #270
Show all (1)

Synthetic Biologics Financials and Metrics

Synthetic Biologics Revenue

USD

Net income (Q2, 2020)

(2.9m)

EBIT (Q2, 2020)

(2.9m)

Market capitalization (8-Feb-2021)

74.2m

Closing stock price (8-Feb-2021)

1.2

Cash (30-Jun-2020)

8.1m

EV

66.8m
Synthetic Biologics's current market capitalization is $74.2 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

General and administrative expense

2.6m5.0m5.8m6.0m8.1m10.1m7.5m5.7m4.6m

R&D expense

3.3m12.3m6.5m14.5m32.9m29.1m18.8m11.8m11.1m

Operating expense total

5.9m17.3m12.3m20.5m41.0m39.3m26.3m17.6m15.7m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

355.6k293.4k

General and administrative expense

694.3k681.8k1.5m1.2m1.1m1.1m1.3m1.9m1.1m1.8m1.2m1.7m2.2m1.6m2.4m2.1m2.1m2.1m1.6m1.7m1.6m1.4m1.5m1.2m1.0m1.1m1.4m1.3m

R&D expense

279.6k289.0k386.0k547.0k763.0k1.1m1.2m1.5m2.7m2.8m3.7m6.5m7.5m10.0m8.2m7.2m7.1m6.1m4.8m4.1m3.4m3.6m2.8m2.4m2.6m4.1m1.6m1.6m

Operating expense total

973.9k970.8k1.9m1.7m1.8m2.2m2.5m3.4m3.8m4.7m4.9m8.2m9.7m11.7m10.6m9.3m9.2m8.1m6.5m5.8m5.0m5.0m4.3m3.6m3.6m5.2m3.0m2.9m
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

6.7m10.0m14.6m17.5m20.8m19.1m17.1m28.9m15.0m

Accounts Receivable

405.0k

Prepaid Expenses

16.0k2.5m1.6m1.5m9.5m827.0k593.0k1.4m

Inventories

2.5m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

8.4m4.6m6.8m5.9m4.5m7.6m6.9m5.1m11.2m7.8m3.3m12.0m4.8m31.8m15.1m10.0m4.5m13.5m13.4m21.1m11.0m7.1m9.5m24.7m21.7m18.7m10.1m8.1m

Accounts Receivable

444.7k494.9k440.0k245.0k122.0k

Prepaid Expenses

75.5k123.8k83.0k94.0k151.0k2.2m1.9m1.6m1.3m1.4m1.4m1.6m7.0m10.3m7.1m5.8m3.1m3.4m1.5m1.3m606.0k535.0k559.0k860.0k1.3m1.2m1.1m897.0k

Current Assets

8.9m8.1m7.3m6.3m4.9m11.5m9.5m6.8m12.5m9.2m4.7m13.6m11.7m42.1m22.2m15.8m7.6m16.8m14.9m22.3m11.6m7.7m10.1m25.6m23.0m19.8m11.2m9.0m
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(8.1m)(17.1m)(12.3m)(19.8m)(44.8m)(27.8m)(15.5m)(13.4m)(15.4m)

Depreciation and Amortization

144.0k63.0k43.0k20.0k72.0k157.0k245.0k272.0k240.0k

Accounts Payable

153.0k7.0k(253.0k)854.0k3.4m(2.4m)27.0k(987.0k)1.3m

Cash From Operating Activities

(2.9m)(8.9m)(7.7m)(16.1m)(38.9m)(27.9m)(20.2m)(17.3m)(13.9m)
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(3.9m)(5.0m)(1.2m)(3.1m)(5.0m)(2.2m)(4.7m)(8.1m)(3.8m)(8.4m)(13.3m)(12.4m)(26.0m)(33.5m)(11.1m)(16.8m)(25.3m)(3.1m)(7.4m)(18.3m)(2.3m)(6.5m)(10.2m)(3.5m)(7.1m)(12.2m)(3.0m)(5.9m)

Depreciation and Amortization

108.1k132.8k20.0k39.0k51.0k11.0k23.0k33.0k3.0k7.0k13.0k8.0k19.0k39.0k37.0k57.0k111.0k57.0k116.0k172.0k71.0k141.0k207.0k62.0k122.0k182.0k58.0k116.0k

Accounts Payable

54.1k(39.7k)(72.0k)(110.0k)2.0k(199.0k)(182.0k)189.0k631.0k937.0k731.0k563.0k7.7m5.0m184.0k143.0k(171.0k)1.8m(270.0k)(895.0k)(527.0k)(803.0k)(1.1m)(267.0k)490.0k1.4m(1.1m)(1.3m)

Cash From Operating Activities

(1.2m)(2.1m)(1.4m)(2.7m)(4.1m)(1.7m)(3.3m)(5.0m)(3.5m)(6.8m)(11.3m)(5.5m)(12.7m)(27.9m)(5.7m)(11.5m)(17.5m)(6.0m)(11.7m)(16.3m)(6.1m)(10.4m)(14.0m)(4.2m)(7.2m)(10.3m)(5.0m)(7.0m)
show all
USDQ2, 2011

Financial Leverage

1 x
Show all financial metrics

Synthetic Biologics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

96/100

Learn more about our premium products
SecurityScorecard logo

Synthetic Biologics Online and Social Media Presence

Synthetic Biologics's Trends

Embed Graph

Synthetic Biologics News and Updates

November 16, 2020

Synthetic Biologics Engages A.G.P./Alliance Global Partners as Advisor to Assist in Evaluating Strategic Options

ROCKVILLE, Md., Nov. 16, 2020 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, today announced it...
November 27, 2019

Synthetic Biologics Reports on NYSE American Noncompliance Notice and Compliance Plan

ROCKVILLE, Md., Nov. 27, 2019 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, today announced it...
August 08, 2019

Synthetic Biologics Reports Second Quarter 2019 Operational Highlights and Financial Results

ROCKVILLE, Md., Aug. 8, 2019 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, today provided an operational update and reported financial...
February 19, 2019

Synthetic Biologics to Report 2018 Year End Operational Highlights and Financial Results on February 27, 2019

ROCKVILLE, Md., Feb. 19, 2019 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health of patients, intends to report operational highlights and financial...
November 21, 2018

Synthetic Biologics Announces Positive Outcome of End-of-Phase 2 Meeting with FDA on SYN-004 (ribaxamase) Development

ROCKVILLE, Md., Nov. 21, 2018 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health of patients, today announced that it has successfully completed an...
November 08, 2018

Synthetic Biologics Reports Third Quarter 2018 Operational Highlights and Financial Results

ROCKVILLE, Md., Nov. 8, 2018 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health of patients, today provided an operational update and reported financial ...
Show more

 Synthetic Biologics Frequently Asked Questions

  • When was Synthetic Biologics founded?

    Synthetic Biologics was founded in 2001.

  • Who are Synthetic Biologics key executives?

    Synthetic Biologics's key executives are Steven Shallcross, Jeffrey J. Kraws and Michael Kaleko.

  • How many employees does Synthetic Biologics have?

    Synthetic Biologics has 11 employees.

  • Who are Synthetic Biologics competitors?

    Competitors of Synthetic Biologics include TG Therapeutics, AcelRx Pharmaceuticals and Neurocrine Biosciences.

  • Where is Synthetic Biologics headquarters?

    Synthetic Biologics headquarters is located at 9605 Medical Center Dr #270, Rockville.

  • Where are Synthetic Biologics offices?

    Synthetic Biologics has an office in Rockville.

  • How many offices does Synthetic Biologics have?

    Synthetic Biologics has 1 office.